SG Americas Securities LLC purchased a new stake in shares of Insmed, Inc. (NASDAQ:INSM) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 7,503 shares of the biopharmaceutical company’s stock, valued at approximately $129,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. State of Wisconsin Investment Board acquired a new stake in shares of Insmed during the second quarter valued at about $789,000. Emerald Advisers Inc. PA increased its position in shares of Insmed by 23.0% during the second quarter. Emerald Advisers Inc. PA now owns 1,285,365 shares of the biopharmaceutical company’s stock valued at $22,057,000 after acquiring an additional 240,048 shares during the last quarter. Goldman Sachs Group Inc. increased its position in shares of Insmed by 3.8% during the first quarter. Goldman Sachs Group Inc. now owns 289,884 shares of the biopharmaceutical company’s stock valued at $5,076,000 after acquiring an additional 10,519 shares during the last quarter. Pictet Asset Management Ltd. increased its position in shares of Insmed by 5.3% during the second quarter. Pictet Asset Management Ltd. now owns 131,143 shares of the biopharmaceutical company’s stock valued at $2,022,000 after acquiring an additional 6,600 shares during the last quarter. Finally, Vanguard Group Inc. increased its position in shares of Insmed by 4.8% during the first quarter. Vanguard Group Inc. now owns 3,781,483 shares of the biopharmaceutical company’s stock valued at $66,214,000 after acquiring an additional 173,532 shares during the last quarter. Institutional investors and hedge funds own 73.08% of the company’s stock.

A number of brokerages have weighed in on INSM. Evercore ISI lifted their price target on shares of Insmed from $28.00 to $40.00 and gave the company an “outperform” rating in a research report on Tuesday, September 5th. Zacks Investment Research upgraded shares of Insmed from a “hold” rating to a “buy” rating and set a $19.00 price target for the company in a research report on Wednesday, July 5th. HC Wainwright reiterated a “buy” rating and set a $35.00 price target on shares of Insmed in a research report on Wednesday, September 6th. Robert W. Baird reiterated a “positive” rating and set a $32.00 price target (up from $23.00) on shares of Insmed in a research report on Wednesday, September 6th. Finally, Citigroup Inc. reiterated a “neutral” rating and set a $17.00 price target (up from $14.00) on shares of Insmed in a research report on Sunday, June 11th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $34.50.

Insmed, Inc. (NASDAQ INSM) opened at 28.50 on Monday. Insmed, Inc. has a one year low of $10.21 and a one year high of $31.39. The company has a 50 day moving average of $17.85 and a 200-day moving average of $17.15. The firm’s market cap is $1.78 billion.

Insmed (NASDAQ:INSM) last posted its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.72) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.63) by ($0.09). On average, equities research analysts predict that Insmed, Inc. will post ($2.70) earnings per share for the current year.

In related news, Director Donald J. Hayden, Jr. sold 45,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 7th. The shares were sold at an average price of $29.67, for a total value of $1,335,150.00. Following the transaction, the director now owns 71,131 shares in the company, valued at $2,110,456.77. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Melvin Md Sharoky sold 50,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $27.37, for a total transaction of $1,368,500.00. The disclosure for this sale can be found here. Company insiders own 5.10% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “SG Americas Securities LLC Invests $129,000 in Insmed, Inc. (INSM)” was first reported by Daily Political and is the property of of Daily Political. If you are viewing this article on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://www.dailypolitical.com/2017/09/25/sg-americas-securities-llc-invests-129000-in-insmed-inc-insm.html.

About Insmed

Insmed Incorporated is a biopharmaceutical company. The Company operates through development and commercialization of therapies for patients with rare diseases segment. Its lead product candidate is ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC).

Institutional Ownership by Quarter for Insmed (NASDAQ:INSM)

Receive News & Ratings for Insmed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed Inc. and related companies with MarketBeat.com's FREE daily email newsletter.